ISI Web of Knowledge Take the next step  
Web of Science®
 
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
The central role of CD4(+) T cells in the antitumor immune response
Author(s): Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H
Source: JOURNAL OF EXPERIMENTAL MEDICINE    Volume: 188    Issue: 12    Pages: 2357-2368    Published: DEC 21 1998  
Times Cited: 653     References: 98     
Abstract: The induction of optimal systemic antitumor immunity involves the priming of both CD4(+) and CDB+ T cells specific for tumor-associated antigens. The role of CD4(+) T helper cells (Th) in this response has been largely attributed to providing regulatory signals required for the priming of major histocompatibility complex class I restricted CD8(+) cytolytic T lymphocytes, which are thought to serve as the dominant effector cell mediating tumor killing. However, analysis of the effector phase of tumor rejection induced by vaccination with irradiated tumor cells transduced to secrete granulocyte/macrophage colony-stimulating factor indicates a far broader role for CD4(+) T cells in orchestrating the host response to tumor. This form of immunization leads to the simultaneous induction of Till and Th2 responses, both of which are required for maximal systemic antitumor immunity. Cytokines produced by these CD4(+) T cell activate eosinophils as well as macrophages that produce both superoxide and nitric oxide. Both of these thee cell types then collaborate within the site of tumor challenge to cause its destruction.
Document Type: Article
Language: English
Reprint Address: Levitsky, H (reprint author), Johns Hopkins Univ, Sch Med, Dept Oncol, 347 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA
Addresses:
1. Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
2. Johns Hopkins Univ, Sch Med, Dept Cardiol, Baltimore, MD 21205 USA
3. Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA
Publisher: ROCKEFELLER UNIV PRESS, 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
Subject Category: Immunology; Medicine, Research & Experimental
IDS Number: 151HA
ISSN: 0022-1007
Previous Record (inactive) Record 1  of  1 Next Record (inactive)
Record from Web of Science®
  
Thomson Reuters Logo